Azalea Therapeutics is enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo. Azalea is pioneering a new way to turn a person’s own T cells into a powerful cancer therapy — directly inside the body. Instead of removing cells and manipulating them in a lab, we use precision genome editing tools to engineer T cells where they already live. At the center of our approach are Enveloped Delivery Vehicles, or EDVs. As highly selective couriers, EDVs are designed to specifically locate T cells within the patient and deliver our genome engineering cargo. Once inside the cell, the anti-cancer agent is inserted into a precise site in the genome, ensuring safe and potent modifications to fortify the T cells against cancers.

Why this matters:

●      We aim to make cell therapy faster and more accessible by avoiding complex manufacturing outside the body.

●      Our platform is designed for precision, so the right cells are safely programmed to effectively fight cancer.

●      This technology has the potential to treat a wide range of cancers with a streamlined, scalable process.

Our goal is simple: develop next-generation delivery technologies to bring genetic engineering and cell therapies to more patients.